2 April 2004

Contents

Conference reports

• Rosiglitazone shows no benefit for lipoatrophy

• Hypertension related to HAART in HIV-positive women

• Testosterone therapy for women with low androgen levels or body weight

• Nevirapine, pregnancy and adverse events

• Prior nevirapine exposure for pregnant women can contribute to treatment failure

• Conflicting findings with HAART use in pregnancy and prematurity

• Antiretrovirals, mode of delivery and transmission risk

• Tenofovir studies in children

• Increase of non-AIDS defining cancers in HOPS cohort

• HIV/HCV coinfection: superiority of pegylated interferon plus ribavirin, but lower response rate compared to mono-infected patients, especially for genotype-1

• Epoetin-alfa improves interferon/ribavirin-associated anaemia

Antiretrovirals

• Gilead discontinues DAPD development

Treatment access

• International community meeting on drug pricing

• Global Fund halts $92 million grant for Ukraine after problems

• Global Fund says it needs $5 billion during 2004-2005

• South African minister of health in line to chair Global Fund

• Thai ddI patent case serves as example to other developing countries, Lancet viewpoint piece says

• UK gives £3 million to WHO’s ‘3 by 5’ treatment goal

Hepatitis coinfection

• International panel issues new guidelines for the care of HIV-HCV coinfected patients

• NICE approves pegylated interferon plus ribavirin in UK

Other news

• New HIV cases in England and Wales increase by 20% in past year

• Micronutrient supplements may enhance survival; research has implications for poor countries

• Durex withdraws N-9 condoms

On the web

• Medical resources